DVAX vs. PRTA, URGN, GTHX, PBYI, RIGL, HALO, IONS, MDGL, ALKS, and FOLD
Should you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include Prothena (PRTA), UroGen Pharma (URGN), G1 Therapeutics (GTHX), Puma Biotechnology (PBYI), Rigel Pharmaceuticals (RIGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), and Amicus Therapeutics (FOLD). These companies are all part of the "medical" sector.
Dynavax Technologies (NASDAQ:DVAX) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.
In the previous week, Prothena had 4 more articles in the media than Dynavax Technologies. MarketBeat recorded 11 mentions for Prothena and 7 mentions for Dynavax Technologies. Prothena's average media sentiment score of 0.75 beat Dynavax Technologies' score of 0.60 indicating that Prothena is being referred to more favorably in the news media.
97.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by company insiders. Comparatively, 28.2% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Dynavax Technologies has a net margin of 3.91% compared to Prothena's net margin of -193.17%. Dynavax Technologies' return on equity of 1.52% beat Prothena's return on equity.
Dynavax Technologies has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500.
Dynavax Technologies currently has a consensus target price of $25.33, indicating a potential upside of 111.29%. Prothena has a consensus target price of $67.00, indicating a potential upside of 221.96%. Given Prothena's higher probable upside, analysts clearly believe Prothena is more favorable than Dynavax Technologies.
Prothena received 133 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 70.67% of users gave Prothena an outperform vote while only 65.77% of users gave Dynavax Technologies an outperform vote.
Dynavax Technologies has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
Dynavax Technologies and Prothena tied by winning 9 of the 18 factors compared between the two stocks.
Get Dynavax Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dynavax Technologies Competitors List
Related Companies and Tools
